Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma

BACKGROUND: Optimal duration of treatment (DoT) with immune checkpoint inhibitors (ICI) in metastatic cancers remains unclear. Many patients, especially those without radiologic complete remission, develop progressive disease after ICI discontinuation. Extending DoT with ICI may potentially improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Tachiki, Lisa May Ling, Hippe, Daniel S., Williams Silva, Karly, Hall, Evan Thomas, McCamy, William, Fritzsche, Dane, Perdue, Andrea, Majovski, Julia, Pulliam, Thomas, Goldstein, Daniel A., Veatch, Joshua, Ho, Joel, Nghiem, Paul T., Thompson, John A., Bhatia, Shailender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576731/
https://www.ncbi.nlm.nih.gov/pubmed/37733060
http://dx.doi.org/10.1007/s00262-023-03539-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576731/
https://www.ncbi.nlm.nih.gov/pubmed/37733060
http://dx.doi.org/10.1007/s00262-023-03539-8

Ejemplares similares